Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 2/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.30 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24129433 | 0.88 | TTR (0.45) | TTRALBMEN1KMT2ACYP2A6 | |
| SCHEMBL18977695 | 0.86 | AR (0.37) | TTRALBMEN1KMT2ACYP2A6 | |
| SCHEMBL2154006 | 0.81 | TTR (0.39) | TTRALBMEN1KMT2ACYP2A6 | |
| SCHEMBL2154905 | 0.81 | TTR (0.39) | TTRALBMEN1KMT2ACYP2A6 | |
| SCHEMBL21938397 | 0.79 | CYP2A6 (0.43) | TTRALBMEN1KMT2ACYP2A6 | |
| SCHEMBL20840177 | 0.77 | LOXL2 (0.41) | TTRALBMEN1KMT2ACYP2A6 | |
| SCHEMBL18300739 | 0.77 | TTR (0.41) | TTRALBMEN1KMT2ACYP2A6 | |
| Hydrochloric Acid SCHEMBL15873813 | 0.76 | LOXL2 (0.40) | TTRALBMEN1KMT2ACYP2A6 | |
| SCHEMBL6589469 | 0.75 | RXRA (0.40) | TTRALBMEN1KMT2AALDH1A1 | |
| SCHEMBL26630683 | 0.74 | TTR (0.54) | TTRALBMEN1KMT2AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. | 2024-01-04 | — | — | US | disclosed |
| EP-4204400-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | Fibrogen, Inc. (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-116348450-A | Compounds, compositions and methods for histone lysine demethylase inhibition | 菲布罗根有限公司 | 2023-06-27 | — | — | CN | disclosed |
| WO-2022047230-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | FIBROGEN, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| CN-102643213-B | Preparation method of 3, 5-dimethyl-4-bromomethylbenzonitrile | JIMING MEDICAL TECHNOLOGY SUZHOU CO LTD | 2014-04-09 | — | — | CN | disclosed |
| CN-102643213-B | Preparation method of 3, 5-dimethyl-4-bromomethylbenzonitrile | JIMING MEDICAL TECHNOLOGY SUZHOU CO LTD | 2014-04-09 | — | — | CN | disclosed |
| US-8476253-B2 | Amide derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-02 | — | — | US | disclosed |
| CN-102643213-A | Preparation method of 3, 5-dimethyl-4-bromomethylbenzonitrile | JIMING MEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-08-22 | — | — | CN | disclosed |
| CN-102643213-A | Preparation method of 3, 5-dimethyl-4-bromomethylbenzonitrile | JIMING MEDICAL TECHNOLOGY SUZHOU CO LTD | 2012-08-22 | — | — | CN | disclosed |
| US-20120071467-A1 | AMIDE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-03-22 | — | — | US | disclosed |
| EP-2409977-A1 | AMIDE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2012-01-25 | — | — | EP | disclosed |
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| WO-1989004305-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071467-A1 | AMIDE DERIVATIVE | CHRM3, CHRM2, TACR2 | TTR 4878/4885ALB 4350/4885MEN1 1905/4885 |
| US-20240002344-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR HISTONE LYSINE DEMETHYLASE INHIBITION | KDM5C, KDM5B, KDM5A | TTR 4552/4885ALB 4705/4885MEN1 3933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.